Clinical trial · no report yet · Phase 3
BE6A LUNG-01
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- NCT06012435 ↗
- Active, not recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- sigvotatug vedotin; docetaxel
- Arms
- Experimental Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 762
- Primary outcomes
- Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Feb 21, 2024
- Primary completion
- May 18, 2026
- Results posted
- No
- Registry record
- NCT06012435 · updated Jul 23, 2026